News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Mariya Rozenblit, MD

Articles by Mariya Rozenblit, MD

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

ByRadhika Appaya,Erika P. Hamilton, MD,Thomas Decker,Hope S. Rugo, MD,Maria Fernandez Abad,Kevin Kalinsky, MD, MS,Qiang Liu,Mariya Rozenblit, MD,Barbara Radecka,Seock-Ah Im,Frances Visco,Alejandro Perez,Yogesh Chattar,Murat Akdere,Vaidyanathan Ganapathy,Sorcha Waters,Joyce O’Shaughnessy, MD

June 27th 2025

Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.

Bolstering Access to Breast Cancer Screening for Genome Markers

ByMariya Rozenblit, MD

December 22nd 2024

Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.

Latest Updated Articles

Trending on CancerNetwork

Lu 177 Plus Immunotherapy Displays Responses in Prostate Cancer

Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

Zanubrutinib Therapies Yield Durable Results in High-Risk, Treatment-Naïve CLL/SLL

Ceralasertib Combo Misses OS End Point in Advanced NSCLC Trial

FDA Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma